DYN - Dyne Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Waltham,
United States
Type: Equity
DYN price evolution
DYN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $610.12 | $273.95 | $123.94 | |
| Short term investments | $170.64 | $181.51 | $1.47 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $736.39 | $792.32 | $488.14 | $129.38 |
| Long term investments | ||||
| Property, plant & equipment | $30.52 | $31.64 | $32.22 | $33.39 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $33.56 | $34.14 | $35.71 | |
| Total investments | $170.64 | $181.51 | $1.47 | |
| Total assets | $768.84 | $825.88 | $522.28 | $165.08 |
| Current liabilities | ||||
| Accounts payable | $6.16 | $1.89 | $7.21 | $22.94 |
| Deferred revenue | ||||
| Short long term debt | $4.78 | $4.76 | $4.72 | |
| Total current liabilities | $43.26 | $29.75 | $22.36 | $51.09 |
| Long term debt | $20.94 | $21.86 | $22.7 | |
| Total noncurrent liabilities | $20.94 | $21.86 | $22.7 | |
| Total debt | $25.72 | $26.62 | $27.41 | |
| Total liabilities | $63.3 | $50.69 | $44.22 | $73.79 |
| Shareholders' equity | ||||
| Retained earnings | -$860.39 | -$763.26 | -$698.16 | -$632.51 |
| Other shareholder equity | $0.48 | -$0.24 | -$0.13 | |
| Total shareholder equity | $775.19 | $478.06 | $91.29 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $123.94 | $174.47 | $200.82 | $300.85 |
| Short term investments | $1.47 | $83.86 | $175.75 | $44.46 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $129.38 | $265.59 | $382.39 | $349.09 |
| Long term investments | ||||
| Property, plant & equipment | $33.39 | $38.41 | $40.96 | $1.95 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $35.71 | $40.73 | $43.27 | $4.25 |
| Total investments | $1.47 | $83.86 | $175.75 | $44.46 |
| Total assets | $165.08 | $306.32 | $425.66 | $353.33 |
| Current liabilities | ||||
| Accounts payable | $22.94 | $5.26 | $4.03 | $3.44 |
| Deferred revenue | ||||
| Short long term debt | $4.72 | $4.61 | $3.89 | |
| Total current liabilities | $51.09 | $28.09 | $28.72 | $10.97 |
| Long term debt | $22.7 | $25.87 | $28.74 | |
| Total noncurrent liabilities | $22.7 | $25.87 | $28.74 | |
| Total debt | $27.41 | $30.48 | $32.64 | |
| Total liabilities | $73.79 | $53.96 | $57.47 | $10.97 |
| Shareholders' equity | ||||
| Retained earnings | -$632.51 | -$396.57 | -$228.47 | -$79.18 |
| Other shareholder equity | -$0.57 | -$0.27 | -$0.03 | |
| Total shareholder equity | $91.29 | $252.36 | $368.2 | $342.37 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $62.26 | $44.54 | $58.84 | |
| Selling, general & administrative | $9.7 | $24.62 | $8.84 | |
| Total operating expenses | $105.66 | $71.96 | $69.16 | $67.69 |
| Operating income | -$71.96 | -$69.16 | -$67.69 | |
| Income from continuing operations | ||||
| EBIT | -$65.1 | -$65.65 | -$66.64 | |
| Income tax expense | ||||
| Interest expense | $9.28 | |||
| Net income | ||||
| Net income | -$97.13 | -$65.1 | -$65.65 | -$66.64 |
| Income (for common shares) | -$65.1 | -$65.65 | -$66.64 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $210.76 | $142.76 | $121.31 | $45.2 |
| Selling, general & administrative | $31.4 | $28.2 | $28.72 | $13.45 |
| Total operating expenses | $242.16 | $170.96 | $150.03 | $58.65 |
| Operating income | -$242.16 | -$170.96 | -$150.03 | -$58.65 |
| Income from continuing operations | ||||
| EBIT | -$235.94 | -$168.1 | -$149.29 | -$59.04 |
| Income tax expense | ||||
| Interest expense | $0.4 | |||
| Net income | ||||
| Net income | -$235.94 | -$168.1 | -$149.29 | -$59.44 |
| Income (for common shares) | -$235.94 | -$168.1 | -$149.29 | -$59.44 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$65.1 | -$65.65 | -$66.64 | |
| Operating activities | ||||
| Depreciation | $0.52 | $0.56 | $0.57 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.74 | $19.91 | $5.73 | |
| Total cash flows from operations | -$54.87 | -$78.54 | -$35.01 | |
| Investing activities | ||||
| Capital expenditures | -$0.86 | -$0.19 | -$0.08 | |
| Investments | $12.03 | -$179.65 | $26.28 | |
| Total cash flows from investing | -$188.07 | $11.17 | -$179.84 | $26.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $379.86 | $408.39 | $0.15 | |
| Net borrowings | ||||
| Total cash flows from financing | $806.26 | $379.86 | $408.39 | $0.15 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $410.16 | $336.17 | $150.01 | -$8.66 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$235.94 | -$168.1 | -$149.29 | -$59.44 |
| Operating activities | ||||
| Depreciation | $2.46 | $3.35 | $0.34 | $0.7 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $19.97 | $15.18 | $17.54 | $6.59 |
| Total cash flows from operations | -$188.16 | -$153.65 | -$119.56 | -$46.51 |
| Investing activities | ||||
| Capital expenditures | -$0.73 | -$3.07 | -$3.62 | -$1.16 |
| Investments | $84.04 | $90.27 | -$134.27 | -$44.5 |
| Total cash flows from investing | $83.31 | $87.2 | -$137.89 | -$45.66 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $54.32 | $37.39 | $157.82 | $246.42 |
| Net borrowings | -$0.06 | |||
| Total cash flows from financing | $54.32 | $37.39 | $157.82 | $380.69 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$50.52 | -$29.05 | -$99.63 | $288.52 |
News
Fundamentals
| Market cap | $1.40B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 101.75M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$294.51M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -4.74 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.89 |
|---|---|
| ROA | -51.62% |
| ROE | N/A |
| Debt/Equity | 0.81 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 17.02 |
| Quick ratio | N/A |